Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 4/20 | 0.40 |
| ▸ | HPN | P05981 | 1/20 | 0.39 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | TNKS | O95271 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.32 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.32 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.32 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.32 |
| ▸ | PDE2A | O00408 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14744842 | 0.91 | PTGDR2 (0.43) | PTGDR2HPNHDAC11PARP1TNKS | |
| SCHEMBL14745185 | 0.80 | PPARG (0.46) | PPARGRAB9AFFAR1 | |
| SCHEMBL14745520 | 0.76 | CYP19A1 (0.44) | PPARGFFAR1 | |
| SCHEMBL14745667 | 0.72 | MGLL (0.37) | PPARGPDE2ASLC6A2P2RY14 | |
| Trifluoroacetic Acid SCHEMBL17598072 | 0.71 | KDR (0.36) | TLR9TLR8TLR7 | |
| SCHEMBL16440961 | 0.70 | KDM4E (0.46) | PPARGRAB9ATLR8TLR7 | |
| SCHEMBL14745557 | 0.70 | KDM4E (0.44) | PPARGFFAR1 | |
| SCHEMBL17597683 | 0.69 | KDR (0.38) | TLR9TLR8TLR7 | |
| SCHEMBL164967 | 0.69 | HPN (0.54) | PTGDR2HPNHDAC11PPARGHDAC6 | |
| Trifluoroacetic Acid SCHEMBL17597457 | 0.69 | CHEK1 (0.36) | TLR9TLR8TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9409905-B2 | Antibacterial compounds and methods for use | PTC THERAPEUTICS, INC. (US) | 2016-08-09 | — | — | US | disclosed |
| US-20150038437-A1 | ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE | PTC THERAPEUTICS, INC. (US) | 2015-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150038437-A1 | ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE | MRPL21, SLC11A2, CLPP | PTGDR2 4594/4885HPN 309/4885HDAC11 2743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.